BCMA as a CAR-T Route: Why It Has Held Its Ground in Multiple Myeloma
This article reviews the BCMA CAR-T route in multiple myeloma: target biology, dual-epitope strategies and why release testing of BCMA-directed constructs depends on reliable target detection reagents.
- Recent Advances
- Product Information
Keywords: BCMA CAR-T, multiple myeloma, TNFRSF17, dual epitope, target detection, release testing, UA011246
Note: The full article is published in Chinese. Please refer to the Chinese version for complete experimental details, figures and product references. For product inquiries, visit www.ua-bio.com.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose 
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Business license (three certificates in one) 
